Developer docs
API playgroundTry for free, no card

Search company profiles

Bellaseno

Full company profile

uuid0007axp

Namestring
Bellaseno
Legal namestring
BellaSeno GmbH
Websiteurl
bellaseno.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

BellaSeno GmbH is a clinical-stage medical device company headquartered in Leipzig, Germany, with an operational site in Brisbane/Burleigh Heads, Australia. The company develops a proprietary bioresorbable scaffold platform built on polycaprolactone (PCL) polymer, engineered with an interconnected porosity architecture to support vascularization and tissue ingrowth without biologics or stem cells. Manufacturing uses a proprietary high-speed additive manufacturing process (referred to as MagLev technology) intended to deliver reproducible quality and scalable production. Product candidates span a breast scaffold (lead focus for reconstruction, revision, and primary augmentation), chest wall/pectus scaffolds, bone regeneration scaffolds, and additional soft-tissue applications, all leveraging the shared PCL platform.

The company is pre-revenue with no commercial product on the market. Its business model centers on clinical development, regulatory approvals, and eventual global commercialization. Marketing channels include medical conferences, a LinkedIn presence, newsletter, earned media, and a dedicated clinical trial website (breastscaffoldtrial.com). Distribution is structured around an exclusive global licensing agreement with Mentor Worldwide LLC (Johnson & Johnson) for the breast scaffold platform, supplementing direct clinical-site engagement across multiple countries. Clinical experience spans 45+ patients across breast, pectus, and bone indications, with longest follow-up of up to six years, and a 19-patient BRV-004 cohort demonstrating 83% volume retention at two years.

Regulatory positioning is established: ISO 13485 certification, EU MDR 2017/745 compliance, and European market access (July 2023) for custom-made bone and pectus scaffolds; CE Mark for the breast scaffold is targeted for 2028 and FDA approval for 2030. Funding to date includes a Series A+B round (with Herbert Stadler as a disclosed investor and Chairman of the Supervisory Board) and a 2024 Australian government grant supporting a fully automated scaffold production facility in Australia.

Short descriptiontext

BellaSeno is a clinical-stage German medtech company developing a proprietary bioresorbable PCL scaffold platform for soft-tissue regeneration, currently focused on breast reconstruction and revision, with global commercialization via an exclusive licensing agreement with Mentor Worldwide LLC (Johnson & Johnson).

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLeipzig, Germany
HQ citystring
Leipzig
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bioresorbable tissue scaffolds, breast reconstruction devices, regenerative medicine, additive manufactured implants, soft tissue regeneration
Industry4 codes
PRIMARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAC
3D Bioprinting & Biofabrication
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHAEAJ
3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Medical Equipment and Supplies Manufacturing3391
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Resorbable Tissue Scaffolds
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales (Future)
TypeHardware Sales
Description

BellaSeno is a clinical-stage company currently focused on clinical development and regulatory approvals. The company is preparing for global market introduction of its breast scaffold platform. An exclusive global licensing agreement with Mentor Worldwide LLC (Johnson & Johnson) will support future commercialization through their established commercial infrastructure.

bellaseno.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Infrastructure, Marketing or Sales, Personnel
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

BellaSeno designs, develops, and manufactures bioresorbable polycaprolactone (PCL) scaffolds that guide soft-tissue regeneration without biologics or stem cells. The scaffolds are produced via proprietary MagLev additive manufacturing and are offered in application-specific forms for breast reconstruction/revision/augmentation, chest wall and pectus excavatum correction, bone regeneration, and other soft-tissue indications. The company is clinical-stage and is preparing for global market introduction through its Mentor Worldwide LLC (Johnson & Johnson) licensing partnership.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 83% volume retention at 2-year follow-up in 19-patient cohort
+2 more records
Product overview1 text field

BellaSeno is a clinical-stage medtech company advancing a bioresorbable scaffold platform for soft-tissue restoration. The company offers a unified platform technology based on proprietary PCL (polycaprolactone) scaffolds with interconnected porosity. The platform is applied across multiple clinical indications: Breast Scaffold (primary focus for reconstruction, revision, and augmentation), Chest Wall/Pectus Scaffold, Bone Regeneration Scaffold, and Other Soft Tissue applications. The scaffolds are designed to guide the body's own tissue formation, providing temporary structure before gradually resorbing and leaving native tissue behind. All products share the core PCL scaffold platform with application-specific designs.

Product and service4 records
1Breast Scaffold
CategoryBioresorbable medical implant - breast applications
Description

Bioresorbable PCL scaffold designed to guide soft tissue formation for breast reconstruction, revision, and primary augmentation procedures. Provides temporary structure supporting fat graft integration before gradually resorbing and leaving native tissue behind. Clinical experience with 45+ patients and up to 6 years follow-up, with 83% volume retention at 2 years in the BRV-004 trial.

2Chest Wall/Pectus Scaffold
CategoryBioresorbable medical implant - chest wall applications
Description

Custom-designed bioresorbable scaffolds for chest wall reconstruction and pectus excavatum correction procedures. Engineered in collaboration with surgeons for anatomical fit while guiding tissue integration. Market access granted in Europe for custom-made pectus excavatum scaffolds.

3Bone Regeneration Scaffold
CategoryBioresorbable medical implant - bone regeneration applications
Description

Resorbable scaffolds designed to stabilize and retain bone graft material in large or complex defects, supporting structured healing and bone regeneration. European market access granted for custom-made bone scaffolds.

4Other Soft Tissue Scaffolds
CategoryBioresorbable medical implant - other soft tissue applications
Description

Bioresorbable scaffold applications extending beyond breast and bone to multiple soft tissue indications where structural support and guided regeneration are required.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Exclusive global licensing agreement bringing together BellaSeno's technology with Mentor's clinical, regulatory, and commercial scale. This collaboration follows positive two-year human clinical data and will accelerate final clinical development of the breast scaffold platform as BellaSeno prepares for global market introduction.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Market-leading breast aesthetics franchise (Natrelle) and parent of regenerative tissue brands; represents the dominant incumbent competitor BellaSeno must displace in breast reconstruction and augmentation.

TypeBroad incumbent
Description

Aesthetics company marketing breast implants (including the Viality tissue expander) for breast augmentation and reconstruction; competes with BellaSeno in the same surgical channel and patient indications.

TypeBroad incumbent
Description

Diversified medical device leader with a portfolio of regenerative scaffolds, dural repair, and wound matrices; comparable technology category (collagen/regenerative matrices used in reconstructive surgery) and broader commercial reach than BellaSeno.

TypeBroad incumbent
Description

Regenerative medicine company marketing wound healing and soft-tissue regeneration products (e.g., Apligraf, Dermagraft) that overlap with BellaSeno's scaffold-driven soft-tissue regeneration value proposition.

TypeEmerging player
Description

Israel-based regenerative aesthetics company developing bio-printed regenerative breast implants using recombinant human collagen; the most technology-comparable peer to BellaSeno's bioresorbable breast scaffold thesis.

TypeDirect peer
Description

Public aesthetics company that markets Motiva breast implants and is investing in regenerative/biology-based breast technologies; competes directly with BellaSeno for surgeon mindshare in breast reconstruction and augmentation.

TypeBroad incumbent
Description

Global breast implant and tissue-expander manufacturer serving the same plastic and reconstructive surgery channel; incumbent competitor for surgeon adoption against BellaSeno's scaffold.

TypeDirect peer
Description

Netherlands-based medical device company developing bioresorbable polymer-based devices for soft-tissue repair and reconstruction; comparable business model (bioresorbable scaffolds for soft tissue) and similar clinical-stage profile.

TypeEmerging player
Description

Polymer-based tissue repair platform combining bioresorbable materials with proprietary adhesion technology for tissue reconstruction; overlaps with BellaSeno on bioresorbable, scaffold-driven soft-tissue regeneration.

TypeBroad incumbent
Description

Non-profit tissue bank providing allograft and regenerative biologic products for reconstruction, sports medicine, and wound healing; adjacent competitor in the regenerative soft-tissue/bone space.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bellaseno

Resorbable Tissue Scaffoldsbellaseno.com

BellaSeno is a clinical-stage German medtech company developing a proprietary bioresorbable PCL scaffold platform for soft-tissue regeneration, currently focused on breast reconstruction and revision, with global commercialization via an exclusive licensing agreement with Mentor Worldwide LLC (Johnson & Johnson).

What Bellaseno does

BellaSeno GmbH is a clinical-stage medical device company headquartered in Leipzig, Germany, with an operational site in Brisbane/Burleigh Heads, Australia. The company develops a proprietary bioresorbable scaffold platform built on polycaprolactone (PCL) polymer, engineered with an interconnected porosity architecture to support vascularization and tissue ingrowth without biologics or stem cells. Manufacturing uses a proprietary high-speed additive manufacturing process (referred to as MagLev technology) intended to deliver reproducible quality and scalable production. Product candidates span a breast scaffold (lead focus for reconstruction, revision, and primary augmentation), chest wall/pectus scaffolds, bone regeneration scaffolds, and additional soft-tissue applications, all leveraging the shared PCL platform.

The company is pre-revenue with no commercial product on the market. Its business model centers on clinical development, regulatory approvals, and eventual global commercialization. Marketing channels include medical conferences, a LinkedIn presence, newsletter, earned media, and a dedicated clinical trial website (breastscaffoldtrial.com). Distribution is structured around an exclusive global licensing agreement with Mentor Worldwide LLC (Johnson & Johnson) for the breast scaffold platform, supplementing direct clinical-site engagement across multiple countries. Clinical experience spans 45+ patients across breast, pectus, and bone indications, with longest follow-up of up to six years, and a 19-patient BRV-004 cohort demonstrating 83% volume retention at two years.

Regulatory positioning is established: ISO 13485 certification, EU MDR 2017/745 compliance, and European market access (July 2023) for custom-made bone and pectus scaffolds; CE Mark for the breast scaffold is targeted for 2028 and FDA approval for 2030. Funding to date includes a Series A+B round (with Herbert Stadler as a disclosed investor and Chairman of the Supervisory Board) and a 2024 Australian government grant supporting a fully automated scaffold production facility in Australia.

Bellaseno firmographics

Firmographics
Name
Bellaseno
Legal name
BellaSeno GmbH
Website
https://bellaseno.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
BellaSeno is a clinical-stage German medtech company developing a proprietary bioresorbable PCL scaffold platform for soft-tissue regeneration, currently focused on breast reconstruction and revision, with global commercialization via an exclusive licensing agreement with Mentor Worldwide LLC (Johnson & Johnson).
Ownership category
akta.pro rank

Bellaseno industry classification

Industry
Product category
Resorbable Tissue Scaffolds
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAC
3D Bioprinting & Biofabrication
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHAEAJ
3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)

Keywords

  • Bioresorbable tissue scaffolds
  • Breast reconstruction devices
  • Regenerative medicine
  • Additive manufactured implants
  • Soft tissue regeneration

Where Bellaseno is headquartered

Location

Headquarters

HQ city
Leipzig
HQ country
Germany
HQ region
Europe

Offices2 records

Markets served

Bellaseno business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Infrastructure, Marketing or Sales, Personnel

Revenue model

  1. Medical Device Sales (Future): BellaSeno is a clinical-stage company currently focused on clinical development and regulatory approvals. The company is preparing for global market introduction of its breast scaffold platform. An exclusive global licensing agreement with Mentor Worldwide LLC (Johnson & Johnson) will support future commercialization through their established commercial infrastructure.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Bellaseno product offering

Product offering

Core offering

BellaSeno designs, develops, and manufactures bioresorbable polycaprolactone (PCL) scaffolds that guide soft-tissue regeneration without biologics or stem cells. The scaffolds are produced via proprietary MagLev additive manufacturing and are offered in application-specific forms for breast reconstruction/revision/augmentation, chest wall and pectus excavatum correction, bone regeneration, and other soft-tissue indications. The company is clinical-stage and is preparing for global market introduction through its Mentor Worldwide LLC (Johnson & Johnson) licensing partnership.

Product overview

BellaSeno is a clinical-stage medtech company advancing a bioresorbable scaffold platform for soft-tissue restoration. The company offers a unified platform technology based on proprietary PCL (polycaprolactone) scaffolds with interconnected porosity. The platform is applied across multiple clinical indications: Breast Scaffold (primary focus for reconstruction, revision, and augmentation), Chest Wall/Pectus Scaffold, Bone Regeneration Scaffold, and Other Soft Tissue applications. The scaffolds are designed to guide the body's own tissue formation, providing temporary structure before gradually resorbing and leaving native tissue behind. All products share the core PCL scaffold platform with application-specific designs.

Differentiator

Problem solved

Functional benefit

Products and services

  • Breast Scaffold Bioresorbable PCL scaffold designed to guide soft tissue formation for breast reconstruction, revision, and primary augmentation procedures. Provides temporary structure supporting fat graft integration before gradually resorbing and leaving native tissue behind. Clinical experience with 45+ patients and up to 6 years follow-up, with 83% volume retention at 2 years in the BRV-004 trial.
  • Chest Wall/Pectus Scaffold Custom-designed bioresorbable scaffolds for chest wall reconstruction and pectus excavatum correction procedures. Engineered in collaboration with surgeons for anatomical fit while guiding tissue integration. Market access granted in Europe for custom-made pectus excavatum scaffolds.
  • Bone Regeneration Scaffold Resorbable scaffolds designed to stabilize and retain bone graft material in large or complex defects, supporting structured healing and bone regeneration. European market access granted for custom-made bone scaffolds.
  • Other Soft Tissue Scaffolds Bioresorbable scaffold applications extending beyond breast and bone to multiple soft tissue indications where structural support and guided regeneration are required.

Quantifiable outcome

  • 83% volume retention at 2-year follow-up in 19-patient cohort
  • +2 more outcomes

Companies that use Bellaseno

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Bellaseno technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Bellaseno partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Mentor Worldwide LLC (Johnson & Johnson)coreStrategic or Co-development PartnerExclusive global licensing agreement bringing together BellaSeno's technology with Mentor's clinical, regulatory, and commercial scale. This collaboration follows positive two-year human clinical data and will accelerate final clinical development of the breast scaffold platform as BellaSeno prepares for global market introduction.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Bellaseno competitors and assessment

Company assessment

Broad incumbents

  • Allergan Aesthetics (AbbVie): Market-leading breast aesthetics franchise (Natrelle) and parent of regenerative tissue brands; represents the dominant incumbent competitor BellaSeno must displace in breast reconstruction and augmentation.
  • Sientra: Aesthetics company marketing breast implants (including the Viality tissue expander) for breast augmentation and reconstruction; competes with BellaSeno in the same surgical channel and patient indications.
  • Integra LifeSciences: Diversified medical device leader with a portfolio of regenerative scaffolds, dural repair, and wound matrices; comparable technology category (collagen/regenerative matrices used in reconstructive surgery) and broader commercial reach than BellaSeno.
  • Organogenesis: Regenerative medicine company marketing wound healing and soft-tissue regeneration products (e.g., Apligraf, Dermagraft) that overlap with BellaSeno's scaffold-driven soft-tissue regeneration value proposition.
  • GC Aesthetics: Global breast implant and tissue-expander manufacturer serving the same plastic and reconstructive surgery channel; incumbent competitor for surgeon adoption against BellaSeno's scaffold.
  • MTF Biologics (Musculoskeletal Transplant Foundation): Non-profit tissue bank providing allograft and regenerative biologic products for reconstruction, sports medicine, and wound healing; adjacent competitor in the regenerative soft-tissue/bone space.

Emerging players

  • CollPlant Biotechnologies: Israel-based regenerative aesthetics company developing bio-printed regenerative breast implants using recombinant human collagen; the most technology-comparable peer to BellaSeno's bioresorbable breast scaffold thesis.
  • Tissium: Polymer-based tissue repair platform combining bioresorbable materials with proprietary adhesion technology for tissue reconstruction; overlaps with BellaSeno on bioresorbable, scaffold-driven soft-tissue regeneration.

Direct peers

  • Establishment Labs: Public aesthetics company that markets Motiva breast implants and is investing in regenerative/biology-based breast technologies; competes directly with BellaSeno for surgeon mindshare in breast reconstruction and augmentation.
  • Polyganics: Netherlands-based medical device company developing bioresorbable polymer-based devices for soft-tissue repair and reconstruction; comparable business model (bioresorbable scaffolds for soft tissue) and similar clinical-stage profile.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Bellaseno social profiles

Digital presence

Bellaseno compliance and trust

Trust signal

Compliance3 records

Bellaseno financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bellaseno leadership team

Management profile

Number of profiles

Profiles12 records

Bellaseno funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bellaseno M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bellaseno

What does Bellaseno do?

BellaSeno designs, develops, and manufactures bioresorbable polycaprolactone (PCL) scaffolds that guide soft-tissue regeneration without biologics or stem cells. The scaffolds are produced via proprietary MagLev additive manufacturing and are offered in application-specific forms for breast reconstruction/revision/augmentation, chest wall and pectus excavatum correction, bone regeneration, and other soft-tissue indications. The company is clinical-stage and is preparing for global market introduction through its Mentor Worldwide LLC (Johnson & Johnson) licensing partnership.

Is Bellaseno a public or private company?

Bellaseno is a private company. It is classified as venture growth investor backed and is currently operating.

When was Bellaseno founded?

Bellaseno was founded in 2017. It employs 11 to 50 people.

Where is Bellaseno based?

Bellaseno is headquartered in Leipzig, Germany, in the Europe region.

How does Bellaseno make money?

One revenue line is on record: medical Device Sales (Future).

Who are Bellaseno's main competitors?

Broad incumbents on record are Allergan Aesthetics (AbbVie), Sientra, Integra LifeSciences, Organogenesis, GC Aesthetics and MTF Biologics (Musculoskeletal Transplant Foundation). Emerging players are CollPlant Biotechnologies and Tissium. Direct peers are Establishment Labs and Polyganics.

Does Bellaseno have an API?

No public API is recorded for Bellaseno.

What industry is Bellaseno in?

Bellaseno's product category is Resorbable Tissue Scaffolds. Its primary akta.pro industry code is HLAAAGAB, Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials), with a secondary code of HLAAAGAC, 3D Bioprinting & Biofabrication. Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
New ScientistBreast-augmentation method uses your own fat in dissolving scaffoldsBellaSeno is trialling an experimental breast augmentation technique that injects a patient's own fat into dissolvable, 3D-printed scaffolds to create natural-looking results without leaving foreign material. The method, developed by researchers at Queensland University of Technology and Macquarie University, has shown promise in earlier reconstruction trials and is currently being tested on first-time augmentation patients. This approach aims to address complications associated with traditional silicone implants, such as rupture risks and the need for future replacements.3D Printing IndustryBellaSeno Expands its Breast Scaffold Trial Following Positive ResultsGerman medical startup BellaSeno has enrolled 30 patients across two Australian clinical trials of its polycaprolactone breast scaffold designed to regenerate tissue without leaving a permanent foreign body, expanding its pivotal trial following positive two-year safety data from an earlier cohort. The first-in-human study of 19 patients showed no scaffold-related complications including capsular contracture or infection, with mean breast volume retention of 83%, while the pivotal trial launched in January 2026 expects to exceed 60 patients by August. If the pivotal trial confirms these results, BellaSeno would have the clinical evidence needed to support regulatory submissions in major markets, positioning it among the few regenerative breast scaffold developers with published human clinical outcomes.VoxelMatters30 women receive 3D printed breast scaffolds in BellaSeno clinical trials | VoxelMatters - The heart of additive manufacturingBellaSeno, a Germany-based medtech company, has now completed breast scaffold procedures on 30 women across its ongoing clinical trials in Australia, including 19 patients from an initial 2021-2023 trial and 11 patients from its Pivotal Clinical Trial launched in January 2026. The initial trial results demonstrated an 83% mean breast volume retention and natural-feeling tissue outcomes after two years with no scaffold-related complications and high patient-reported satisfaction. The company is building evidence for commercialization as dozens more women remain enrolled in the ongoing pivotal trial.BioWorldBellaseno speeds breast scaffold trial as J&J deal clears path to marketBellaseno GmbH is accelerating its absorbable breast scaffold development, with a pivotal Australian trial recruiting faster than expected. A licensing deal with Johnson & Johnson subsidiary Mentor Worldwide positions the technology for global commercialization.GlobeNewswireLes échafaudages régénératifs de BellaSeno annoncent l’avènement d’une nouvelle ère pour la chirurgie mammaireBellaSeno has treated 30 women with its regenerative breast scaffolds, including 11 in the pivotal trial. The material is polycaprolactone, and no complications occurred in the first study. The company expects patient numbers to more than double by August.GlobeNewswireBellaSeno’s regenerative scaffolds signal new era for breast surgeryThirty Australian women have undergone breast surgery using BellaSeno's absorbable polycaprolactone scaffolds, following successful safety trials. The company's pivotal trial, launched in January 2026, has enrolled 11 patients, with more scheduled. The company aims to build a robust evidence base for future commercialization.PharmiWeb.comBreast Implants Market Size 2025, Emerging Trends, In-Depth Analysis, Demand Drivers, and Forecast InsightsThe global breast implants market is projected to expand at a CAGR of approximately 8% over the forecast period, driven by rising demand for cosmetic procedures, technological advancements, and increasing medical tourism. Recent product launches and clinical achievements are reshaping the competitive landscape, including Johnson & Johnson's introduction of the FDA-approved MENTOR MemoryGel Enhance line (December 2024), BellaSeno's promising early clinical trial results for resorbable 3D-printed breast scaffolds (October 2024), and Establishment Labs' FDA approval for Motiva Implants marking its entry into the U.S. market (September 2024). The report segments the market by product type, shape, application, and region through 2030.GlobeNewswireBellaSeno Establishes High-Profile Clinical Advisory BoardBellaSeno GmbH announced the establishment of a seven-member Clinical Advisory Board of board-certified plastic surgeons and clinicians. The board will support the company's pivotal clinical trial of resorbable breast implants, which is scheduled to be initiated in the coming months.Business & Financial3D-Printed Grafts: Shaping The Future Of Bone And Tissue RegenerationEuropean researchers are developing 3D-printed bone grafts and bioprinting to repair complex bone defects, using patient cells and smart implants. Projects like SBR and BellaSeno are advancing clinical use, but long-term safety studies and regulatory hurdles remain. The technology could become routine in surgery, offering personalized regenerative treatments.